PBA
AXSM icon

Paradigm Biocapital Advisors’s Axsome Therapeutics AXSM Stock Holding History

Paradigm Biocapital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-520,080
Closed -$23.2M – 24
2022
Q3 		$23.2M Buy
+520,080
New +$26M 3.09% 15

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Paradigm Biocapital Advisors's AXSM Position: Q4 2022 in Review

Paradigm Biocapital Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2022, closing a stake of 520,080 shares — an estimated $23.2M sold.

Paradigm Biocapital Advisors first reported a position in AXSM in Q3 2022 and held it in 1 quarter. The position peaked at $23.2M in Q3 2022. 219 funds tracked by Wall St. Rank hold AXSM as of Q4 2022.

  • Paradigm Biocapital Advisors reported no remaining Axsome Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 520,080 Axsome Therapeutics shares in Q4 2022, an estimated $23.2M.
  • Paradigm Biocapital Advisors first reported a position in Axsome Therapeutics in Q3 2022 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Axsome Therapeutics position peaked at $23.2M in Q3 2022.
  • 219 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.